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SPECIES DIFFERENCES IN SENSITIVITY OF T LYMPHOCYTES TO IMMUNOSUPPRESSIVE EFFECTS OF 
FK 506 1 
FK 506 is a novel immunosuppressive drug isolated from 
Strepcomyce! csukubaeruu in 1984 (1). Initial in vitro studies 
have mdicated that FK 506 is a potent inhibitor of murine and 
human mixed lymphocyte reactions and can prevent the gen· 
eration of cytolytic cells. FK 506 suppresses T cell-dependent 
responses and this effect appears to be mediated through the 
inhibition of interleukin·2 release and diminished expression 
of the IL·2 receptor on activated T cella (2. 3). The strong 
immunosuppressive effect of FK 506 has been observed during 
primary actlvatlon of lymphocytes. such aa the mised leukocyte 
reaction and the secondary proliferation of alloreactave T lym· 
phocytes genersted from MLR or propagated from organ trans-
plant biopsies as measured by the pnmed lymphocyte test (4). 
Although both FK 506 and cyclosponne nhibit similar mech-
anisms of action. the immunoauppressive effect of FK 506 is 
several· hundred-fold greater than that of CsA. Synergism be-
tween the two drugs haa been observed in vivo and in vitro. as 
1 Thil work wa. ,upporteci by Granca AJ·2:U67 and HL·36416 from 
the National In.ucutft of Health. 
demonstrated by significant immunosuppressive effects of com· 
binations of drugs at low dOBes that are individually ineffective 
(5, 6). Synergism has also been noted between FK 506 and 
azathioprine ( 7). 
In vivo studies have also established the effectiveness of FK 
506 in several allograft models. Todo et al. showed that FK 506 
greatly prolongs allograft survival of heterotopic hean traDl' 
plants in rata (8-10). and renal and liver transplants in dop 
( 11). In these experiments. FK 506 was found to be effectivl 
at dose levels of 1-1.5 mg/kg/day-however. preliminary stud-
ies with kidney transplants performed in baboons indicated 
that this dose of FK 506 was ineffective in prolonging graft 
SUrvival (12). In vitro atudies were conducted to quantitate tbI 
lInmunosuppreSSlve effects of FK 506 on the MLR with lym-
phocytes from baboons. dogs. rata. and humans. 
Heparinized blood was collected from normal dogs (0-9" 
rata (n-3). baboons (n-1O) and humans (n-8). Mononua..· 
cella were isolated by Ficoll·Hypaque sedimentation and UDlf 
directional MLR cultures were set up in triplicate WIth equM 
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FlCURE 1. 1050 valull {or FK 506 in MLR cultures from rata. 
. bUIIIaD. dop. and baboon •• Each point repreaentl one experiment done 
iA triplicate. Statiatical anaJyai. of the 1050 valull wu done using the 
~ Studant'l t telt. The analyail wu done for baboons VI. dogs 
IDIi baboon. VI. human •. 
nlllDbers (lO'/mi) of responders and irradiated stimulators in 
10" autologous serum and incubated for 6 days at 37"C and 
6" CO,. During the final 20 hr of incubation. each culture was 
labeled with 1 "Ci of [3HJ-thymidine (lCN Radiochemicals. 1 
mCi/mil, harvested. and counted in a liquid scintillation coun-
ter. The dose effect of FK 506 and CsA on MLR activity was 
meuured at different concentratlons of the drug ranging from 
0.03-10 ng/ml for FK 506 to 3.5-2500 ng/ml for CsA. For each 
culture the 1050 dose was calculated as the concentration of 
FK 506 or CsA that cauaed a 50% inhibition of the MLR. 
Fi«ure 1 illustrate. that the 1050 of FK 506 was about 10-
fold higher for baboon lymphocytes j3.85±2 ng/mU than for 
lymphocytes from the other three species I rats 0.33±O.2 ng/ml: 
humans O.29±O.2 ng/ml: dogs O.S9±O.58 ng/mll. These differ-
ences in FK 506 sensitivity were statisticaily significant 
(P<o.ooll. Similar differences between LD50 values were ob-
aerved for CsA. although their magnitudes were somewhat 
lower t Fig. 2). The 1050 of CsA was Significantly higher for 
baboons t212±161 ng/ml) than for rats 14S±4 ng/mll: humans 
(1iO.5±28.5 ng/mll and dogs 140.8±IB.S ng/mll. These data also 
en.end prevIous observations that FK 506 is 100-300 times 
more potent In inhibiting MLR than CsA (4l. 
Comparable differences in FK506 sensltivitv were observed 
in vlvo In different allograft models. Table 1 summarizes the 
IUrvaval rates oi kidney transplants in baboons versus kidney 
transplants In dogs and cardiac transplants In rats. In the 
baboon and dog model. FK 506 was administered oraily. in the 
I'It blodel the drult was administered intramuscularly. Success-
ful J)rolonltatlon oi RT -1- i ncompluble cardiac alloJf&it in ratl 
... aclueved at FK506 dosea of 1.28 mit/kg/day WIth a mean 
IlUmval of 99 dava 110). where .. untreated allografts only 
IIUrwived 6 days. At daily do ... of 1.5 mltl kg/day. FK 506 
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FIGURE 2. IDSO values for CsA in MLR cultures from rata. humans. 
dop. and baboons. Each point representa one experiment done an 
triplicate. 
TABLE 1. Effect of FK 506 on alloltl'aft survival in the three animal 
species 
Specie.- FK treatment Survival 
(n; (ml/k,/day) (ciaya; 
Rata (6) 1.28 99±61 
Canine j6) 1.5 61±33 
Baboons (2) 2 16±3 
Baboons j6) 12 67±26 
Baboons (6) 18 90±44 
• Cardiac transplant in rata. renal transplant in caninel and baboons. 
prolonged allogeneic renal transplants from mongrel to bealtle 
dogs from 14 days to 61 days (I I). However. a similar dose of 
FK 506 (2 mg/kg/day) induced a modest and insignificant 
prolongation of renal transplant survival in baboons (16 days 
versus 9 days for untreated controls). Considerably higher doses 
of FK 506 (12 and 18 mg/kg/day) were necessary for baboons 
to achieve allograft survivals comparable to those observed in 
rats and dogs at lower doses (Table 11. 
The results of these in vivo and in vitro studies demonstrate 
species differences in sensitivity in the immunosuppressive 
effects of FK 506. The baboon model requires almost teniold 
higher doses of FK 506 than the rat and dog models to achieve 
optimal immunosuppressIon. The in vitro assays indicate that 
FK 506 senSitivity of human lymphocytes is more similar to 
that for dogs and rats rather than baboons. These lindings 
suggest that FK 506 at doses of 1.5 mg/kg/day might prOVide 
effective immunosuppression of human allografts. However 
only clinical trials can establish the optimal administration of 
this drug. 
In transplant patients the optimization of immunosuppres-
sive treatment depends on the administratIon of appropriate 
doses that have minimal side effects and the momtonng of drug 
levels_ Pharmacokinetlc and pharmacodYnamic evaluations 
have aided in developing Individualized immunosuppressIve 
therapy 113'. Furthermore drug sensltivitv of in vitro lympho-
cyte act.ivltion Mem. useful. and conSIderable variation. have 
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been seen between different individuals (14). In this study 
species differeneea in FK 506 sensitivity of MLR reflect the 
efficacy of FK 506 treatment in prolonging allograft survival. 
Thus in vitro studies of drug sensitivity of lymphocyte activa-
tion are useful in determining optimal drug doses to ensure 
successful transplantation. 
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